IMMP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immutep Ltd (IMMP) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong upside potential as highlighted by analysts, with a bull case projecting a 279% increase. Despite neutral technical indicators and no recent trading signals, the stock's clinical advancements and potential in immunotherapy make it an attractive long-term investment opportunity.
The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 51.888, and moving averages are converging, suggesting no clear trend. Key support is at 2.579, and resistance is at 2.922.
Analysts have given an Outperform rating with a $6 price target, citing strong clinical results for eftilagimod alpha. The stock has a 9.61% chance to increase in the next month based on historical patterns.
No significant hedge fund or insider activity. Technical indicators do not show a strong bullish signal. The stock has an 80% chance to decline slightly (-0.56%) in the next day and -1.67% in the next week.
No financial data available for analysis.
Citizens initiated coverage with an Outperform rating and a $6 price target. Analysts highlight strong clinical results and significant upside potential, with a bull case of 279% and a bear case of 62% downside.
